Efficacy and safety of ASP0819 in patients with fibromyalgia

Takeaway

  • ASP0819 had a good tolerability profile and demonstrated findings suggestive of efficacy in patients with fibromyalgia.

Why this matters ?

  • Fibromyalgia pathophysiology is not fully understood, but peripheral processes including C-fiber hyperexcitability are thought to be involved, and while treatments are typically opioid-based, non-opioid agents targeting these mechanisms, such as ASP0819, may be beneficial.

  • The tolerability and efficacy of ASP0819 raises the potential of novel non-opioid treatment options for fibromyalgia patients which may be beneficial given opioid-associated risks for addiction and overdose, as well as lack of evidence of their efficacy in treating fibromyalgia.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.